Table 3. Published definitions of complete remission (or response) in Lupus nephritis (1990 – 2015) (studies with n ≥70 patients)

First author (ref.)	Study design	Definition of remission components							Remission achieved (%)
		Proteinuria [1]	Renal function	Urine sediment	Serological activity	Serum albumin	Treatment	Duration	
Moroni (1)	Observational	<0.2	Normal	–	–	–	–	–	38.5%
Bono (2)	Observational	N/D	N/D	N/D	N/D	N/D	None	–	19%
Mok (3)	Observational	<0.3	Normal GFR	–	–	Normal	–	–	64%
Ioannidis (4)	Observational	Reduction by ≥30% to <3	Stable or improving CrCl, an improvement of CrCl by ≥30% if the baseline SCr was ≤2.5 mg/dL or stable CrCl if the baseline SCr was >2.5 mg/dL	Inactive [2]	–	–	–	–	74.1%
Korbet (5)	Observational	≤0.33	SCr ≤1.4 mg/dl	–	–	–	–	–	43%
Najafi (6)	Observational	≤0.33	SCr ≤1.4 mg/dl	–	–	–	–	–	43%
Hill (7)	Observational	≤0.33	SCr ≤123 µmol/L	–	–	–	–	–	Not reported
Illei (8)	RCT	<1	SCr <130% of the lowest SCr since start of treatment	Inactive	–	–	Only AM and prednisolone ≤10 mg/day allowed	≥6 months	50.3%
Martins (9)	Observational	<0.5	N/D	Inactive	–	–	–	–	31%
Mok (10, 11)	Observational	<1	Stabilization or improvement in SCr	Inactive	Improved	–	–	≥6 months	55–59%
Wang (12)	Observational	<1	SCr <1.2 mg/dl	Inactive	–	–	–	≥6 months	44.4%
Ginzler (13)	RCT	≤10% above upper NL	≤10% above upper NL	Inactive	–	–	–	–	14.3% (at 6 months)
Grootscholten	RCT	<0.5	SCr <130% of the lowest SCr since start of	Inactive	–	–	–	–	Not reported (shown in

(14)			treatment						figure)
Moroni (15)	Observational	<0.2	SCr ≤1.2 mg/dl, and 25% increase of baseline CrCl if abnormal, or stable value if normal at baseline	Inactive	–	–	–	–	82%
Lee (16)	Observational	<0.2	SCr <1.2 mg/dl	Inactive	–	–	–	≥6 months	52%
Mak (17)	Observational	<1	Stabilization or improvement in SCr	Inactive	Improved	–	–	≥6 months	60.4%
Chen (18)	Observational	≤0.33	SCr ≤1.4 mg/dl	–	–	–	–	–	43%
Sun (19)	Observational	≤0.4	Normal	Inactive	–	Normal	–	–	58%
Gibson (20)	Observational	<0.2	eGFR ≥90 ml/min/1.73m^2 or ≤25% increase from baseline	Inactive	–	–	–	–	24.7%
Al Arfaj (21)	Observational	<0.5	Normal SCr (improved CrCl)	–	–	–	–	–	76%
Yu (22)	Observational	<0.3	Normal	Inactive	–	Normal	–	–	24%
Appel (23)	RCT	≤0.5	Normal	Inactive	–	–	–	–	8.4% (at 6 months)
Cortes-Hernandez (24)	Observational	<0.3	Normal eGFR or ±10% if previously abnormal	Inactive	–	–	–	–	34% (at 12 months)
Houssiau (25)	RCT	<1	SCr ≤1.4 mg/dl	Inactive	–	–	–	–	
Ayodele (26)	Observational	<0.2	Stable eGFR (if normal at baseline), or increase in eGFR by 25% (if abnormal at baseline)	–	–	–	–	–	44.8%
Singh (27)	Observational	<0.5	SCr ≤UL of normal range, ≤15% greater than baseline, if baseline SCr is within the normal range	–	–	–	–	–	Not reported
Moon (28)	Observational	<0.2	GFR ≥90 ml/min/1.73m^2 or >25% increase from baseline	Inactive	–	–	–	–	41.1% (at 12 months)
Reich (29)	Observational	<0.3	SCr ≤1.4 mg/dl (120 mmol/l)	–	–	–	–	–	74.5%

So (30)	Observational	≤0.5	SCr ≤1.4 mg/dl	Inactive	–	–	–	–	50.4%
Zeher (31)	RCT	<0.5	SCr within 10% of normal value	Inactive	–	–	–	–	19.8% (at 6 months)
Chen (32)	RCT	<0.5	Normal SCr or ≤15% more than baseline values	Inactive	–	≥35 g/L	–	–	45.7% (at 6 months)
Alsuwaida (33)	Observational	≤0.33	SCr ≤125 µmol/L	–	–	–	–	–	41.6%
Dhir (34)	Observational	<0.2	SCr ≤1.5 mg/dl	Inactive	–	–	–	–	54.6%
Wang (35)	Observational	<0.3	Normal SCr	Inactive	–	Normal	–	–	32.7%
Moroni (36)	Observational	<0.2	SCr <1.2 mg/dL, and 25% increase of baseline CrCl if abnormal, or stable value if normal at baseline	Inactive	–	–	–	–	70.9%
Chen (37)	RCT	<0.3	Normal SCr or not >15% baseline values	Inactive	–	≥35 g/L	–	–	60%
Rovin (38)	RCT	<0.5	Normal SCr (if abnormal at baseline), or SCr ≤115% of baseline (if normal at baseline)	Inactive	–	–	–	–	28.5% (at 12 months)
Mysler (39)	RCT	<0.5	SCr with ≤25% increase from baseline	–	–	–	–	–	36.3%
Furie (40)	RCT	<0.26	eGFR ≥90% of initial level	Inactive	–	–	–	≥4 weeks	21.8%
Access Trial Group (41)	RCT	<0.5	SCr of ≤1.2 mg/dl or ≤125% of baseline	–	–	–	Prednisone ≤10 mg/day at week 12	–	32/1% (at 6 months)
Mok (42)	RCT	<0.2	Normal SCr or ≤25% above baseline	Inactive	–	–	–	–	60.7% (at 6 months)
Liu (43)	RCT	≤0.4	Normal	Inactive	–	≥35 g/L	–	–	35.6% (at 6 months)
Mahmoud (44)	Observational	<0.2	SCr ≤1.2 mg/dl, and 25% increase of baseline CrCl if abnormal, or stable if abnormal at baseline	Inactive	–	–	–	–	59.3%
Koo (45)	Observational	<0.3	N/D	–	–	–	–	≥6 months	42.5%
Fernandes das	Observational	<0.2	Normal	–	Absent	–	–	≥5 years	38.1%

[1] Proteinuria determined by 24-hr urine collection and/or urine protein-to-creatinine ration
[2] Defined as absence of significant glomerular hematuria and/or urine casts
Abbreviations: N/D, not described, CrCl, creatinine clearance, GFR, glomerular filtration rate, RCT, randomized controlled trial, AM, antimalarial

References

1. Moroni G, Quaglini S, Maccario M, Banfi G, Ponticelli C. "Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int 1996;50:2047-53.
2. Bono L, Cameron JS, Hicks JA. The very long-term prognosis and complications of lupus nephritis and its treatment. QJM 1999;92:211-8.
3. Mok CC, Wong RW, Lau CS. Lupus nephritis in Southern Chinese patients: clinicopathologic findings and long-term outcome. Am J Kidney Dis 1999;34:315-23.
4. Ioannidis JP, Boki KA, Katsorida ME, Drosos AA, Skopouli FN, Boletis JN, et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 2000;57:258-64.
5. Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J, Rohde RD. Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis 2000;35:904-14.
6. Najafi CC, Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J, et al. Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. Kidney Int 2001;59:2156-63.
7. Hill GS, Delahousse M, Nochy D, Thervet E, Vrtovsnik F, Remy P, et al. Outcome of relapse in lupus nephritis: roles of reversal of renal fibrosis and response of inflammation to therapy. Kidney Int 2002;61:2176-86.
8. Illei GG, Takada K, Parkin D, Austin HA, Crane M, Yarboro CH, et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum 2002;46:995-1002.
9. Martins L, Rocha G, Rodrigues A, Santos J, Vasconcelos C, Correia J, et al. Lupus nephritis: a retrospective review of 78 cases from a single center. Clin Nephrol 2002;57:114-9.
10. Mok CC, Ying KY, Ng WL, Lee KW, To CH, Lau CS, et al. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med 2006;119:355 e25-33.
11. Mok CC, Ying KY, Tang S, Leung CY, Lee KW, Ng WL, et al. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum 2004;50:2559-68.
12. Wang LC, Yang YH, Lu MY, Chiang BL. Retrospective analysis of the renal outcome of pediatric lupus nephritis. Clin Rheumatol 2004;23:318-23.
13. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005;353:2219-28.
14. Grootscholten C, Ligtenberg G, Hagen EC, van den Wall Bake AW, de Glas-Vos JW, Bijl M, et al. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int 2006;70:732-42.
15. Moroni G, Quaglini S, Gallelli B, Banfi G, Messa P, Ponticelli C. The long-term outcome of 93 patients with proliferative lupus nephritis. Nephrol Dial Transplant 2007;22:2531-9.
16. Lee BS, Cho HY, Kim EJ, Kang HG, Ha IS, Cheong HI, et al. Clinical outcomes of childhood lupus nephritis: a single center's experience. Pediatr Nephrol 2007;22:222-31.
17. Mak A, Mok CC, Chu WP, To CH, Wong SN, Au TC. Renal damage in systemic lupus erythematosus: a comparative analysis of different age groups. Lupus 2007;16:28-34.

18. Chen YE, Korbet SM, Katz RS, Schwartz MM, Lewis EJ, Collaborative Study G. Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol 2008;3:46-53.
19. Sun HO, Hu WX, Xie HL, Zhang HT, Chen HP, Zeng CH, et al. Long-term outcome of Chinese patients with membranous lupus nephropathy. Lupus 2008;17:56-61.
20. Gibson KL, Gipson DS, Massengill SA, Dooley MA, Primack WA, Ferris MA, et al. Predictors of relapse and end stage kidney disease in proliferative lupus nephritis: focus on children, adolescents, and young adults. Clin J Am Soc Nephrol 2009;4:1962-7.
21. Al Arfaj AS, Khalil N, Al Saleh S. Lupus nephritis among 624 cases of systemic lupus erythematosus in Riyadh, Saudi Arabia. Rheumatol Int 2009;29:1057-67.
22. Yu F, Tan Y, Liu G, Wang SX, Zou WZ, Zhao MH. Clinicopathological characteristics and outcomes of patients with crescentic lupus nephritis. Kidney Int 2009;76:307-17.
23. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009;20:1103-12.
24. Cortes-Hernandez J, Torres-Salido MT, Medrano AS, Tarres MV, Ordi-Ros J. Long-term outcomes--mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases. Nephrol Dial Transplant 2010;25:3939-48.
25. Houssiau FA, D'Cruz D, Sangle S, Remy P, Vasconcelos C, Petrovic R, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 2010;69:2083-9.
26. Ayodele OE, Okpechi IG, Swanepoel CR. Predictors of poor renal outcome in patients with biopsy-proven lupus nephritis. Nephrology (Carlton) 2010;15:482-90.
27. Singh S, Zhou XJ, Ahn C, Saxena R. A retrospective analysis of clinical presentation of lupus nephritis. Am J Med Sci 2011;342:467-73.
28. Moon SJ, Kwok SK, Ju JH, Park KS, Park SH, Cho CS, et al. Predictors of chronic kidney disease in Korean patients with lupus nephritis. J Rheumatol 2011;38:2588-97.
29. Reich HN, Gladman DD, Urowitz MB, Bargman JM, Hladunewich MA, Lou W, et al. Persistent proteinuria and dyslipidemia increase the risk of progressive chronic kidney disease in lupus erythematosus. Kidney Int 2011;79:914-20.
30. So MW, Koo BS, Kim YG, Lee CK, Yoo B. Predictive value of remission status after 6 months induction therapy in patients with proliferative lupus nephritis: a retrospective analysis. Clin Rheumatol 2011;30:1399-405.
31. Zeher M, Doria A, Lan J, Aroca G, Jayne D, Boletis I, et al. Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis. Lupus 2011;20:1484-93.
32. Chen W, Tang X, Liu Q, Chen W, Fu P, Liu F, et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: A multicenter randomized clinical trial. Am J Kidney Dis 2011;57:235-44.
33. Alsuwaida A, Husain S, Alghonaim M, AlOudah N, Alwakeel J, ullah A, et al. Strategy for second kidney biopsy in patients with lupus nephritis. Nephrol Dial Transplant 2012;27:1472-8.
34. Dhir V, Aggarwal A, Lawrence A, Agarwal V, Misra R. Long-term outcome of lupus nephritis in Asian Indians. Arthritis Care Res (Hoboken) 2012;64:713-20.
35. Wang YF, Xu YX, Tan Y, Yu F, Zhao MH. Clinicopathological characteristics and outcomes of male lupus nephritis in China. Lupus 2012;21:1472-81.
36. Moroni G, Quaglini S, Gravellone L, Gallelli B, Leoni A, Messa P, et al. Membranous nephropathy in systemic lupus erythematosus: long-term outcome and prognostic factors of 103 patients. Semin Arthritis Rheum 2012;41:642-51.
37. Chen W, Liu Q, Chen W, Tang X, Fu P, Liu F, et al. Outcomes of maintenance therapy with tacrolimus versus azathioprine for active lupus nephritis: a multicenter randomized clinical trial. Lupus 2012;21:944-52.
38. Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012;64:1215-26.
39. Mysler EF, Spindler AJ, Guzman R, Bijl M, Jayne D, Furie RA, et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum 2013;65:2368-79.

40. Furie R, Nicholls K, Cheng TT, Houssiau F, Burgos-Vargas R, Chen SL, et al. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol 2014;66:379-89.
41. Group AT. Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study. Arthritis Rheumatol 2014;66:3096-104.
42. Mok CC, Ying KY, Yim CW, Siu YP, Tong KH, To CH, et al. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. Ann Rheum Dis 2014.
43. Liu Z, Zhang H, Liu Z, Xing C, Fu P, Ni Z, et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med 2015;162:18-26.
44. Mahmoud GA, Zayed HS, Ghoniem SA. Renal outcomes among Egyptian lupus nephritis patients: a retrospective analysis of 135 cases from a single centre. Lupus 2015;24:331-8.
45. Koo HS, Kim S, Chin HJ. Remission of proteinuria indicates good prognosis in patients with diffuse proliferative lupus nephritis. Lupus 2016;25:3-11.
46. Fernandes das Neves M, Irlapati RV, Isenberg D. Assessment of long-term remission in lupus nephritis patients: a retrospective analysis over 30 years. Rheumatology (Oxford) 2015;54:1403-7.